Description
Reta is an investigational synthetic peptide that acts as an agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.
Research Focus
Clinical research has investigated retatrutide in relation to glucose metabolism, energy balance, bodyweight regulation and metabolic physiology. Its triple-receptor activity distinguishes it from therapies that act on only one or two of these receptor systems.
Scientific Context
Phase 2 clinical studies have evaluated retatrutide in adults with obesity and in people with type 2 diabetes, examining measures including bodyweight and glycaemic control. Gastrointestinal adverse events were among the commonly reported effects in these studies.
Important Research Note
Retatrutide remains an investigational compound. Clinical-trial findings should be interpreted within the specific study population, formulation and protocol, and should not be interpreted as evidence that an AXEN LABS research product is safe or effective for weight management, diabetes treatment or any other human application.
For research purposes only. Not intended for human or veterinary use.
